<DOC>
	<DOC>NCT01421472</DOC>
	<brief_summary>To demonstrate whether addition of MM-121 to paclitaxel is more effective than treatment with paclitaxel alone, when administered as part of the neoadjuvant treatment in Her2 negative locally advanced operable breast cancer patients.</brief_summary>
	<brief_title>A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer</brief_title>
	<detailed_description>This is a multicenter, open-label, randomized, Phase II study of preoperative MM-121 with paclitaxel in HER2-negative breast cancer. Patients will be randomized to receive paclitaxel with or without MM-121 for 12 weeks followed by 4 cycles of doxorubicin plus cyclophosphamide and subsequent surgery.</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Histological confirmation of ER positive, HER2 negative invasive breast cancer (Group 1) or invasive triplenegative breast cancer (Group 2) Free of metastatic disease ≥ 18 years old Female Had no prior treatment for any cancer Eligible for treatment with paclitaxel, doxorubicin and cyclophosphamide Have a history of severe allergic reactions to paclitaxel or other drugs formulated in Cremaphor® EL Are pregnant or breastfeeding</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Neoadjuvant</keyword>
	<keyword>Her2 negative</keyword>
	<keyword>Her2 non-overexpressing</keyword>
	<keyword>Estrogen Receptor Positive</keyword>
	<keyword>Triple Negative</keyword>
	<keyword>MM-121</keyword>
	<keyword>Paclitaxel</keyword>
</DOC>